295 results on '"Alazawi, William"'
Search Results
2. Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD
3. Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice
4. National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022
5. Non-invasive Tests of Fibrosis: Does One Size Fit All?
6. A global research priority agenda to advance public health responses to fatty liver disease
7. Renal dysfunction in liver disease
8. Measuring NAFLD models of care
9. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group
10. Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank
11. The contribution of daytime sleepiness to impaired quality of life in NAFLD in an ethnically diverse population
12. WED-275 Understanding barriers to adoption of clinical guidelines for metabolic dysfunction-associated steatotic liver disease among hepatologists in Europe
13. THU-236-YI Oxysterol treatment causes indirect stellate cell activation: a potential mechanism linking steroid metabolising enzyme dysregulation with fibrosis
14. WED-248 A four-country modelling study on doubling MASH diagnostic rates by 2027
15. Socioeconomic Factors Associated With Liver-Related Mortality From 1985 to 2015 in 36 Developed Countries
16. Nonalcoholic Fatty Liver Disease
17. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
18. Authors’ reply to McKenna-Barry and Ryan
19. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke : findings from matched cohort study of 18 million European adults
20. Improving prevention strategies for cardiometabolic disease
21. A global action agenda for turning the tide on fatty liver disease
22. A global action agenda for turning the tide on fatty liver disease
23. Renal dysfunction in liver disease
24. Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study
25. National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022
26. Automated and reproducible cell identification in mass cytometry using neural networks
27. Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease
28. Abnormalities of the genome and transcriptome in the progression of cervical neoplasia
29. Atypical Chemokine receptors regulate the induction of ‘disease-associated’ LSEC by modulating Endothelial-to-Mesenchymal transition (EndMT) during liver fibrosis
30. A social media listening study of patients’ experiences toward NAFLD (LISTEN-NAFLD)
31. The national audit of non-alcoholic fatty liver disease (NAFLD) identifies variations and shortfalls in delivery of care in the UK
32. Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)
33. Low rates of fibrosis scoring in the primary care records of 5987 people living with type 2 diabetes
34. A systematic review and meta-analysis of the prevalence and cross-sectional severity of South Asian patients with non-alcoholic fatty liver disease
35. B-cell activating factor in non-alcoholic steatohepatitis
36. Developing a risk stratification tool for advanced NAFLD fibrosis using routinely measured clinical variables in a diabetes clinic annual review
37. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts
38. Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol
39. Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease
40. A global research priority agenda to advance public health responses to fatty liver disease
41. Update on Treatment for Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis.
42. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
43. 883 - MÉDICOS EN EUROPA
44. Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis
45. Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity
46. Pharmacology and therapeutic potential of interferons
47. Myeloid XBP1 links lipid overload with inflammation in NASH: Do advances in basic science have clinical potential?
48. Factors associated with HCC stage at presentation and survival in an ethnically diverse UK population
49. Investigating the function of Endothelial-To-Mesenchymal transition during liver fibrogenesis using a Liver-On-A-Chip platform
50. Pro-inflammatory liver-homing T cells in peripheral blood, liver and adipose tissue in patients with NASH and changes in post-bariatric surgery samples
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.